Virios Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.virios.com
- Introduction
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Virios Therapeutics, Inc.
- Target Recruit Count
- 422
- Registration Number
- NCT04748705
- Locations
- 🇺🇸
IMC Study Site, Everett, Washington, United States
🇺🇸IMC Study SIte, Prairie Village, Kansas, United States
News
Virios Therapeutics and Wex Pharmaceuticals Merge to Form Dogwood Therapeutics, Advancing Novel Pain and Viral Therapies
Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.